Roche, TRMS start another T-20 trial

Roche (SWX:ROCZ) and Trimeris (TRMS) will begin an international open-label Phase III trial of T-20, an HIV fusion inhibitor, in combination with oral antiretrovirals to treat HIV in up to 450 patient...